A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients

Abstract

Background and objectives. - A notable proportion of COVID-19 patients need statins for their co-existing conditions. Statins possess several anti-inflammatory properties. We have attempted to describe potential association of exposure to statins and severity of COVID symtpoms in a historical study in hospitalized COVID-19 patients. Methods .- This single-center, historical cohort study was performed in Baharloo hospital as a referral hospital for COVID-19 patients in Tehran. Patients were divided into two groups; 163 statins users and 547 non-users. Mortality rate, intensive care unit (ICU) admission and length of hospitalization were compared between studied groups. In addition, during the investigation, pre-existing conditions were evaluated for groups. If a significant difference was observed between groups, the feature was considered in the adjustment of the odds ratio. Results.- At the beginning, statistical analysis study showed that statins users had significantly (p <0.0001) higher mortality rate, ICU admission and length of hospitalization. But after implementation of variables such as age, sex, diabetes, hypertension status, stroke, dyslipidemia, cardiovascular diseases, chronic kidney disease (CKD), corticosteroids, renin-angiotensin-aldosterone axis inhibitors and proton pump inhibitors (PPIs) for adjustment of the odds ratio, a considerable alteration appeared in the studied values. Following adjustment of odds ratio it was shown that statins did not change mortality (95% CI, OR 0.71 (0.41-1.22), p= 0.22), ICU admission (95% CI, OR 1.05 (0.66-1.66), p= 0.835) and length of hospitalization (95% CI, OR 1.30 (0.78-2.17), p= 0.311). In addition, we found that statins could not decrease inflammatory markers in COVID-19 infected patients. Conclusion.- The use of statins did not seem to change outcomes in COVID19.

Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study

“… 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 In 11 studies, ratio measures were close to 1. 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 In 2 studies, an increased risk was observed. 58 , 59 Most of these studies were conducted in hospitalized patients and/or patients tested for COVID‐19.…”

The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

“…On the other hand, in the present investigation, we found that statin use was associated with an increased risk of ICU admission in our mostly Black cohort. Another study conducted in Tehran found that, on univariate analysis, the use of statins was significantly associated with mortality rate, ICU admission, and length of hospitalization [41]. A study previously conducted at our hospital (Detroit Medical Center) found that statins were associated with reduced mortality in their COVID-19 cohort, consisting of mostly Black individuals, while they found no difference in ICU admission [42].…”